PRIMARY IMMUNODEFICIENCY DISEASES (PID)
Clinical trials for PRIMARY IMMUNODEFICIENCY DISEASES (PID) explained in plain language.
Never miss a new study
Get alerted when new PRIMARY IMMUNODEFICIENCY DISEASES (PID) trials appear
Sign up with your email to follow new studies for PRIMARY IMMUNODEFICIENCY DISEASES (PID), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug shows promise for long-term immune deficiency treatment
Disease control CompletedThis study checked the long-term safety of TAK-771 in 15 Japanese patients with primary immunodeficiency disease (PID). Participants received TAK-771 injections for up to 3 years. The main goal was to monitor side effects and immune reactions. The study is now complete.
Matched conditions: PRIMARY IMMUNODEFICIENCY DISEASES (PID)
Phase: PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New shot option for immune deficiency shows promise in early trial
Disease control CompletedThis study tested a new medicine called TAK-881, a concentrated antibody solution given under the skin, in 65 people with primary immunodeficiency diseases (PIDD). The goal was to see how well the body absorbs it and if it is safe compared to an existing treatment (HYQVIA). Parti…
Matched conditions: PRIMARY IMMUNODEFICIENCY DISEASES (PID)
Phase: PHASE2, PHASE3 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
VR goggles ease needle pain for kids with rare immune disorder
Symptom relief CompletedThis study tested whether watching virtual reality or a tablet video can reduce pain and fear in children aged 4-11 with primary immunodeficiency during the needle stick for their IVIG treatment. 31 children participated, and researchers measured their pain, fear, and vital signs…
Matched conditions: PRIMARY IMMUNODEFICIENCY DISEASES (PID)
Phase: NA • Sponsor: Dr. Hatice Dönmez • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC